JP2006509752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509752A5 JP2006509752A5 JP2004554318A JP2004554318A JP2006509752A5 JP 2006509752 A5 JP2006509752 A5 JP 2006509752A5 JP 2004554318 A JP2004554318 A JP 2004554318A JP 2004554318 A JP2004554318 A JP 2004554318A JP 2006509752 A5 JP2006509752 A5 JP 2006509752A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- chloride
- composition according
- ethyl
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- -1 2- (2,3-dihydrobenzofuran-5-yl) -1-methylethyl Chemical group 0.000 claims 5
- 206010069632 Bladder dysfunction Diseases 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010046543 Urinary incontinence Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 claims 3
- 229960002016 oxybutynin chloride Drugs 0.000 claims 3
- 229960003510 propiverine Drugs 0.000 claims 3
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 claims 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010053236 Mixed incontinence Diseases 0.000 claims 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 2
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 2
- 229960002677 darifenacin Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 208000020629 overactive bladder Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003855 solifenacin Drugs 0.000 claims 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 2
- 208000022170 stress incontinence Diseases 0.000 claims 2
- 229950000334 temiverine Drugs 0.000 claims 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims 2
- 229960004045 tolterodine Drugs 0.000 claims 2
- 206010046494 urge incontinence Diseases 0.000 claims 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 2
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 claims 1
- CXDSZFRIMJUZKT-MRGWGSTCSA-N (4r,5s)-5-[[(e,2r,3r)-3-(1,3-benzodioxol-5-yl)-6-(1,3-benzoxazol-2-yl)hex-5-en-2-yl]-(naphthalen-2-ylmethyl)carbamoyl]-1,3-dioxolane-2,2,4-tricarboxylic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CN([C@@H]([C@H](C\C=C\C=1OC2=CC=CC=C2N=1)C=1C=C2OCOC2=CC=1)C)C(=O)[C@H]1OC(C(O)=O)(C(O)=O)O[C@H]1C(O)=O CXDSZFRIMJUZKT-MRGWGSTCSA-N 0.000 claims 1
- AYOYFVLAAQPHJT-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[2-(6,7-dimethyl-3,4-dihydronaphthalen-2-yl)ethyl]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.C=1C=2C=C(C)C(C)=CC=2CCC=1CCN1CCCC1 AYOYFVLAAQPHJT-WLHGVMLRSA-N 0.000 claims 1
- ZUBLNWRGQSNWGQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-yl n-(2-phenylphenyl)carbamate;hydrochloride Chemical compound Cl.C1CN(CC2)CCC12OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 ZUBLNWRGQSNWGQ-UHFFFAOYSA-N 0.000 claims 1
- DXPNKUPZWZIRSS-UHFFFAOYSA-N 4,4-diphenylcyclopent-2-en-1-amine;hydrochloride Chemical compound Cl.C1=CC(N)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 DXPNKUPZWZIRSS-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 1
- 241001553014 Myrsine salicina Species 0.000 claims 1
- RNGHAJVBYQPLAZ-UHFFFAOYSA-N Terodiline hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 RNGHAJVBYQPLAZ-UHFFFAOYSA-N 0.000 claims 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 claims 1
- 229960002123 bethanechol chloride Drugs 0.000 claims 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 claims 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 claims 1
- 229960002236 emepronium Drugs 0.000 claims 1
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 claims 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims 1
- 229960002978 fesoterodine Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 claims 1
- 229960002102 imipramine hydrochloride Drugs 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 229960005434 oxybutynin Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960001491 trospium Drugs 0.000 claims 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 1
- 229960001530 trospium chloride Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026546A EP1424079A1 (en) | 2002-11-27 | 2002-11-27 | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| PCT/EP2003/012331 WO2004047838A2 (de) | 2002-11-27 | 2003-11-05 | Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509752A JP2006509752A (ja) | 2006-03-23 |
| JP2006509752A5 true JP2006509752A5 (https=) | 2006-12-21 |
Family
ID=32241298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004554308A Pending JP2006509751A (ja) | 2002-11-27 | 2003-11-03 | β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物 |
| JP2004554318A Pending JP2006509752A (ja) | 2002-11-27 | 2003-11-05 | β−３アドレナリン受容体アゴニスト及び抗ムスカリン作用薬を含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004554308A Pending JP2006509751A (ja) | 2002-11-27 | 2003-11-03 | β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050261328A1 (https=) |
| EP (4) | EP1424079A1 (https=) |
| JP (2) | JP2006509751A (https=) |
| KR (1) | KR20050088295A (https=) |
| CN (1) | CN1717230A (https=) |
| AT (1) | ATE399005T1 (https=) |
| AU (2) | AU2003285312A1 (https=) |
| BR (1) | BR0316535A (https=) |
| CA (2) | CA2507266A1 (https=) |
| CO (1) | CO5580754A2 (https=) |
| DE (1) | DE50310046D1 (https=) |
| EA (1) | EA009781B1 (https=) |
| EC (1) | ECSP055814A (https=) |
| ES (1) | ES2309371T3 (https=) |
| HR (1) | HRP20050467A2 (https=) |
| MX (1) | MXPA05005483A (https=) |
| NO (1) | NO20053088L (https=) |
| PL (1) | PL376259A1 (https=) |
| RS (1) | RS20050392A (https=) |
| UA (1) | UA81931C2 (https=) |
| WO (2) | WO2004047830A2 (https=) |
| ZA (1) | ZA200503282B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| WO2005042021A2 (de) * | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
| DE10356112A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
| CA2580170A1 (en) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| EP1809591A1 (en) * | 2004-10-26 | 2007-07-25 | Kissei Pharmaceutical Co., Ltd. | Synthesis of phenoxyacetic acid derivatives |
| CA2599158C (en) * | 2005-02-25 | 2011-01-25 | Astellas Pharma Inc. | Pharmaceutical agent comprising solifenacin |
| US20060165776A1 (en) * | 2005-08-31 | 2006-07-27 | Ramesh Sesha | Antidepressant oral pharmaceutical compositions |
| EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| US9440003B2 (en) * | 2005-11-04 | 2016-09-13 | Boston Scientific Scimed, Inc. | Medical devices having particle-containing regions with diamond-like coatings |
| FR2895259B1 (fr) * | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
| JP5124286B2 (ja) * | 2006-01-10 | 2013-01-23 | キッセイ薬品工業株式会社 | 徐放性製剤およびその製造方法 |
| BRPI0711606A2 (pt) * | 2006-05-22 | 2012-02-14 | Teva Pharma | formulações de hidrocloreto de duloxetina de liberação retardada |
| US20090175935A1 (en) * | 2006-08-14 | 2009-07-09 | Torrent Research Ltd. | Pharmaceutical compositions of duloxetine |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| US20080226711A1 (en) * | 2007-03-12 | 2008-09-18 | Torrent Pharmaceuticals Ltd. | Pharmaceutical compositions of duloxetine |
| WO2009066181A2 (en) * | 2007-07-09 | 2009-05-28 | Combino Pharm, S.L. | Oral delayed-release duloxentine hydrochloride pellets |
| CA2704298C (en) | 2007-11-02 | 2015-07-21 | Astellas Pharma Inc. | Pharmaceutical composition for treating overactive bladder |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| ES2376095B1 (es) * | 2008-10-02 | 2013-01-24 | Laboratorios Del Dr. Esteve, S.A. | Pellets entéricos de duloxetina. |
| WO2010053068A1 (ja) * | 2008-11-07 | 2010-05-14 | 大日本住友製薬株式会社 | 新規で有用な下部尿路症状治療剤 |
| EP2316432A1 (de) * | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| EP2377525A1 (en) * | 2010-03-26 | 2011-10-19 | Laboratorios del Dr. Esteve S.A. | Duloxetine enteric pellets |
| ES2665467T3 (es) | 2010-03-29 | 2018-04-25 | Astellas Pharma Inc. | Composición farmacéutica de liberación modificada |
| AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| TW201338772A (zh) * | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
| BR112015005351A2 (pt) * | 2012-09-18 | 2017-07-04 | Taris Biomedical Llc | sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior |
| PL224543B1 (pl) | 2013-08-21 | 2017-01-31 | Pabianickie Zakłady Farm Polfa Spółka Akcyjna | Dojelitowa tabletka duloksetyny |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| WO2017066572A1 (en) * | 2015-10-15 | 2017-04-20 | Duke University | State-dependent peripheral neuromodulation to treat bladder dysfunction |
| ES2967863T3 (es) | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| EP3448367A1 (en) | 2016-04-25 | 2019-03-06 | Synthon BV | Tablets comprising mirabegron and solifenacin |
| US10543174B2 (en) | 2016-04-25 | 2020-01-28 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| CA2061665C (en) * | 1991-02-25 | 2002-04-16 | Mark Mortensen Foreman | Treatment of lower urinary tract disorders |
| IL104567A (en) * | 1992-02-03 | 1997-03-18 | Fujisawa Pharmaceutical Co | Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| WO1997015549A1 (en) * | 1995-10-26 | 1997-05-01 | Tokyo Tanabe Company Limited | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME |
| CN1083831C (zh) * | 1996-01-10 | 2002-05-01 | 旭化成株式会社 | 新的三环化合物及含有它们的药物组合物 |
| PT888330E (pt) * | 1996-03-11 | 2003-09-30 | Lilly Co Eli | Metodos de tratamento ou prevencao de cistite intersticial |
| WO1998003067A1 (en) * | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| JP4685201B2 (ja) * | 1996-08-19 | 2011-05-18 | キッセイ薬品工業株式会社 | 頻尿および尿失禁の予防・治療剤 |
| WO1998021184A1 (en) * | 1996-11-14 | 1998-05-22 | Pfizer Inc. | Process for substituted pyridines |
| WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
| JPH1112171A (ja) * | 1997-06-19 | 1999-01-19 | Nisshin Flour Milling Co Ltd | 消化器疾患治療薬 |
| ID24062A (id) * | 1997-07-25 | 2000-07-06 | Kissei Pharmaceutical | Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing |
| ATE266639T1 (de) * | 1997-10-17 | 2004-05-15 | Yamanouchi Pharma Co Ltd | Amidderivate oder deren salze |
| WO1999031045A1 (en) * | 1997-12-18 | 1999-06-24 | Kissei Pharmaceutical Co., Ltd. | Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| EP1070046A1 (en) * | 1998-04-06 | 2001-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
| DE69919860T2 (de) * | 1998-04-14 | 2005-08-25 | Kissei Pharmaceutical Co., Ltd., Matsumoto | 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| MY126489A (en) * | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
| DE69942928D1 (de) * | 1998-08-27 | 2010-12-23 | Pfizer Health Ab | Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung |
| DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
| DE60015036T2 (de) * | 1999-07-23 | 2006-03-02 | Pfizer Products Inc., Groton | Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste |
| HUP0203028A3 (en) * | 1999-11-11 | 2005-07-28 | Pharmacia Ab | Pharmaceutical formulation containing tolterodine and its use |
| US6562368B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| PT1257277E (pt) * | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| JP5684964B2 (ja) * | 2000-06-07 | 2015-03-18 | ワトソン ファーマシューティカルズ， インコーポレイテッド | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| US6514991B2 (en) * | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
| CA2431041A1 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| GB0102408D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Chemical compounds |
| EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| WO2002085871A2 (en) * | 2001-04-04 | 2002-10-31 | Wyeth | Serotonergic agents with long-acting in vivo effects |
| WO2003035600A1 (en) * | 2001-10-19 | 2003-05-01 | Fujisawa Pharmaceutical Co., Ltd. | Process for producing benzocycloheptene derivative |
| MXPA04003806A (es) * | 2001-11-05 | 2005-04-08 | Upjohn Co | Aerosol antimuscarinico. |
| KR20050005410A (ko) * | 2002-02-19 | 2005-01-13 | 파마시아 코포레이션 | 요실금 치료용으로서의 시클로옥시게나제 저해제 및항무스카린제의 용도 |
-
2002
- 2002-11-27 EP EP02026546A patent/EP1424079A1/en not_active Withdrawn
-
2003
- 2003-03-11 UA UAA200506227A patent/UA81931C2/uk unknown
- 2003-11-03 ES ES03778298T patent/ES2309371T3/es not_active Expired - Lifetime
- 2003-11-03 EA EA200500776A patent/EA009781B1/ru not_active IP Right Cessation
- 2003-11-03 CN CNA2003801044257A patent/CN1717230A/zh active Pending
- 2003-11-03 JP JP2004554308A patent/JP2006509751A/ja active Pending
- 2003-11-03 MX MXPA05005483A patent/MXPA05005483A/es not_active Application Discontinuation
- 2003-11-03 RS RSP-2005/0392A patent/RS20050392A/sr unknown
- 2003-11-03 DE DE50310046T patent/DE50310046D1/de not_active Expired - Fee Related
- 2003-11-03 CA CA002507266A patent/CA2507266A1/en not_active Abandoned
- 2003-11-03 AU AU2003285312A patent/AU2003285312A1/en not_active Abandoned
- 2003-11-03 HR HR20050467A patent/HRP20050467A2/xx not_active Application Discontinuation
- 2003-11-03 EP EP05027827A patent/EP1640000A3/de not_active Withdrawn
- 2003-11-03 KR KR1020057009414A patent/KR20050088295A/ko not_active Withdrawn
- 2003-11-03 EP EP03778298A patent/EP1572181B1/de not_active Expired - Lifetime
- 2003-11-03 WO PCT/EP2003/012225 patent/WO2004047830A2/de not_active Ceased
- 2003-11-03 PL PL03376259A patent/PL376259A1/xx unknown
- 2003-11-03 AT AT03778298T patent/ATE399005T1/de not_active IP Right Cessation
- 2003-11-03 BR BR0316535-3A patent/BR0316535A/pt not_active IP Right Cessation
- 2003-11-05 CA CA002507343A patent/CA2507343A1/en not_active Abandoned
- 2003-11-05 WO PCT/EP2003/012331 patent/WO2004047838A2/de not_active Ceased
- 2003-11-05 JP JP2004554318A patent/JP2006509752A/ja active Pending
- 2003-11-05 AU AU2003289854A patent/AU2003289854A1/en not_active Abandoned
- 2003-11-05 EP EP03782183A patent/EP1567149A2/de not_active Withdrawn
-
2005
- 2005-04-22 ZA ZA200503282A patent/ZA200503282B/en unknown
- 2005-05-23 EC EC2005005814A patent/ECSP055814A/es unknown
- 2005-05-24 US US11/136,148 patent/US20050261328A1/en not_active Abandoned
- 2005-05-24 US US11/136,165 patent/US20090012161A9/en not_active Abandoned
- 2005-06-23 NO NO20053088A patent/NO20053088L/no not_active Application Discontinuation
- 2005-06-27 CO CO05062906A patent/CO5580754A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006509752A5 (https=) | ||
| JP2006509751A5 (https=) | ||
| RU2404771C3 (ru) | Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты | |
| US20050261328A1 (en) | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | |
| ES2315425T3 (es) | Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos. | |
| US20170216212A1 (en) | Tapentadol compositions | |
| US8846765B2 (en) | Pharmaceutical combination | |
| US7005449B2 (en) | Tolterodine salts | |
| CA2795253A1 (en) | Methods of improving quality of sleep | |
| KR20040044953A (ko) | 요실금 치료를 위한, 무스카린 길항제와 선택된오피오이드와의 배합물 | |
| MXPA04003806A (es) | Aerosol antimuscarinico. | |
| JP5792067B2 (ja) | αアドレナリン受容体拮抗薬と抗ムスカリン薬の併用 | |
| RU2008112176A (ru) | Профилактическое или терапевтическое средство для заболевания, вызванного уменьшением количества слезной жидкости | |
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| JP2007509897A (ja) | β−３−アドレノセプターアゴニスト及びα−アゴニストから成る医薬組成物 | |
| US20070078181A1 (en) | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | |
| JP2005503424A (ja) | 尿疾患の治療用医薬組成物 | |
| EP1434574A2 (en) | Tolterodine metabolites | |
| CN1518444B (zh) | 取代的6-二甲基氨基甲基-1-苯基环己烷化合物在制备治疗尿失禁的药物中的用途 | |
| US20080167317A1 (en) | Combination Therapy | |
| EP3513787A1 (en) | Use of beta-adrenergic inverse agonists for smoking cessation | |
| HK1085917A (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |